ZFIN Image: Meyers et al., 2012, Fig. 2

Image

Figure Caption

Fig. 2

Dose and timing-response for 1-azakenpaullone on retinal development. The GSK3β inhibitor 1-azakenpaullone was applied to embryos at various stages of development and observations were made at 72 hpf. While control embryos treated with 0.1% DMSO as early as dome stage developed normally (A), treatment with 2.5 µM 1-azakenpaullone (Az) at dome or shield stage resulted in loss of forebrain and eyes (B, C). Treatment with 2.5 µM 1-azakenpaullone at 90% epiboly resulted in a small eye lacking a lens (D). At bud-stage or later, treatment with 1-azakenpaullone led to a small eye, with the size of the eye increasing with progressively later treatments (E-J). The effects of 1-azakenpaullone are dose-dependent: embryos treated at shield stage with 0.5 µM 1-azakenpaullone have relatively normal development (K), 1 µM results in a small eye (L), and treatments at 2.5 µM or higher results in failure of eye development (M-O). Scale bar = 200 µm.

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Neural Dev.